Rajan P Kulkarni
Overview
Explore the profile of Rajan P Kulkarni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
2110
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fey R, Billo A, Clister T, Doan K, Berry E, Tibbitts D, et al.
Cancers (Basel)
. 2025 Mar;
17(5).
PMID: 40075580
In the era of precision medicine, mounting evidence suggests that the time of therapy administration, or chronotherapy, has a great impact on treatment outcomes. Chronotherapy involves planning treatment timing by...
2.
Valdez C, Sanchez-Zuno G, Osmani L, Ibrahim W, Galan A, Bacchiocchi A, et al.
Oncotarget
. 2024 Jul;
15:507-520.
PMID: 39028303
Macrophage Migration Inhibitory Factor (MIF) and its homolog D-dopachrome Tautomerase (DDT) have been implicated as drivers of tumor progression across a variety of cancers. Recent evidence suggests MIF as a...
3.
Fey R, Nichols R, Tran T, Vandenbark A, Kulkarni R
Cancers (Basel)
. 2024 May;
16(9).
PMID: 38730725
Immune checkpoint blockade (ICB) therapy is used to treat a wide range of cancers; however, some patients are at risk of developing treatment resistance and/or immune-related adverse events (irAEs). Thus,...
4.
Garrison Z, Clister T, Bleem E, Berry E, Kulkarni R
Cancers (Basel)
. 2024 Mar;
16(5).
PMID: 38473384
BRAF-mutant melanoma patients can be treated with targeted therapy or immunotherapies, and it is not clear which should be provided first. Targeted treatments do not work in up to one-third...
5.
Clister T, Fey R, Garrison Z, Valenzuela C, Bar A, Leitenberger J, et al.
Cells
. 2024 Feb;
13(3.
PMID: 38334658
Healthy human skin tissue is often used as a control for comparison to diseased skin in patients with skin pathologies, including skin cancers or other inflammatory conditions such as atopic...
6.
Van Buren I, Madison C, Kohn A, Berry E, Kulkarni R, Thompson R
JAMA Netw Open
. 2023 Oct;
6(10):e2340695.
PMID: 37906189
Importance: Systemic steroids are commonly used to manage immune-related adverse events (irAEs), but it remains unclear whether they may undermine immune checkpoint inhibitor (ICI) therapy outcomes. Few studies have assessed...
7.
Pavlick A, Ariyan C, Buchbinder E, Davar D, Gibney G, Hamid O, et al.
J Immunother Cancer
. 2023 Oct;
11(10).
PMID: 37852736
Since the first approval for immune checkpoint inhibitors (ICIs) for the treatment of cutaneous melanoma more than a decade ago, immunotherapy has completely transformed the treatment landscape of this chemotherapy-resistant...
8.
Garrison Z, Hall C, Fey R, Clister T, Khan N, Nichols R, et al.
Life (Basel)
. 2023 Apr;
13(4).
PMID: 37109503
The past decade has seen numerous advancements in approaches to melanoma detection, each with the common goal to stem the growing incidence of melanoma and its mortality rate. These advancements,...
9.
Adler F, Anderson A, Bhushan A, Bogdan P, Bravo-Cordero J, Brock A, et al.
Cell Syst
. 2023 Apr;
14(4):252-257.
PMID: 37080161
Collective cell behavior contributes to all stages of cancer progression. Understanding how collective behavior emerges through cell-cell interactions and decision-making will advance our understanding of cancer biology and provide new...
10.
Kashani-Sabet M, Leachman S, Stein J, Arbiser J, Berry E, Celebi J, et al.
JAMA Dermatol
. 2023 Mar;
159(5):545-553.
PMID: 36920356
Importance: Therapy for advanced melanoma has transformed during the past decade, but early detection and prognostic assessment of cutaneous melanoma (CM) remain paramount goals. Best practices for screening and use...